



Media release

Ad hoc announcement pursuant to Art. 53 LR

SHL Telemedicine announces transformative, accretive acquisition of majority stake in Mediton Group, a leading B2B healthcare services provider in Israel

The acquisition contributes to all of SHL's financial parameters from day one

- *Mediton Group is profitable and growing, with strong B2B healthcare offering business that is complementary to SHL's Israel B2C business*
- *The acquisition doubles SHL's annual revenues in Israel to a level of NIS 140 – 150 million (USD 43 – 46 million) and EBITDA of NIS 45-50 million (USD 14 – 15.5 million)*
- *In 2021, Mediton Group is expected to generate revenues of NIS 65 – 70 million (USD 20 – 22 million) and EBITDA of NIS 20 – 22 million (USD 6 – 7 million)*
- *SHL expects that the synergy from the acquisition will increase its annual revenues in Israel to NIS 185 – 200 million (USD 57 – 62 million) within 3 years*

Tel Aviv / Zurich, 25 August 2021 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, today announced it has signed an agreement to acquire 70% of the Mediton Group companies. The acquisition is accretive to SHL as of day one.

The Mediton Group with its 220 employees is a leading provider of B2B healthcare services in Israel in the field of diagnostics, preventive medicine, and medical opinions to institutional customers, including Israeli blue-chip companies, government institutions including the Israeli Social Security and Ministry of Defense, all four sick funds and to insurance companies.

SHL Telemedicine will acquire a 70% interest in Mediton Group for approx. USD 26 million (NIS 84 million) on a cash-free debt-free basis adjusted by net working capital and will finance the acquisition from cash on hand and long-term bank financing. The transaction has a put and call option that will allow the transfer to SHL of the remaining 30% interest in approximately four to five years from closing. The Mediton Group will continue to operate under its current leadership.

The agreement contains customary sellers' reps and warranties, as well as sellers' indemnification, non-compete and non-solicitation undertakings. The transaction is expected to close within 30 days subject to satisfaction of customary closing conditions.

"Following the capital increase earlier this year, this is a major step in our ambition to significantly grow SHL Telemedicine. The passion and dedication of the Mediton Group leadership team makes it the perfect company to expand our footprint in the Israeli market to the B2B healthcare services offering, continuing to implement our growth strategy in all our territories," said Mr.



Yariv Alroy, Chairman of SHL Telemedicine. “We welcome the Mediton Group to the SHL family, and we are excited about the many opportunities ahead.”

“SHL Telemedicine and Mediton Group share the same fundamental values with a strong focus on providing high quality services to their customers” commented Dr. Haim Perluk, founder and Chairman of the Mediton Group. “We will continue to deliver the exceptional levels of service Mediton provides to our customers across Israel, and we have no doubt that we will go from strength to strength, to the benefit of all stakeholders.”

About the Mediton Group (*Mediton Medical Centers Ltd.*)

Founded in 1990 and by its Chairman Dr. Haim Perluk, Mediton is a network of leading medical centers in the field of providing services and private medicine. Mediton aims to add and improve the medical services using state-of-the-art equipment, responsiveness and flexibility to customer needs, at a high professional level and uncompromising quality of service.

Investor and media conference call at 10.00 am cet today

Yariv Alroy, Chairman, Erez Nachtoy, CEO, and Yossi Vadnagra, CFO, will discuss the transaction and answer questions. A presentation is available on www.shl-telemedicine.com/news. The conference will be held in English.

Date Wednesday, 25 August 2021
Time 10.00 am CET

For the video call please click on this link to [Join Zoom Meeting](#)

Meeting ID: 861 1971 4311
Passcode: 177853

Or dial by your location
+972 55 330 1762 (Israel)
+41 44 529 92 72 (Switzerland)
+1 929 205 6099 US (New York)

Find your local number: <https://us02web.zoom.us/j/86119714311>

Further information

Elisabeth Wallimann, IRF, Phone: +41 43 244 81 41, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.